A small provider of infection prevention products continues to attract plenty of investor attention as new licence agreements could help drive significant growth in the world’s largest market. However, as our update here suggests, it's very hard to gauge the market potential
Byotrol: new licence agreements see shares leap againShares in Byotrol (LON:BYOT), the infection prevention and control technology company, leaped on news of two new license agreements and confirmation of continued strong trading. The group has agreed a technology license over Byotrol24, its EPA registered long-lasting germ kill sanitiser spray, with a consortium of investors and experienced market professionals under the umbrella of Integrated Resources International LLC. The license is for 10 years and gives exclusive rights over Byotrol 24 in the Americas. In return for those rights, IRI has paid to Byotrol an initial license fee of US$250k and will…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login